Central Drug Research Institute investigators have synthesized novel compounds conjugating the quinoline moiety with a piperazine/pyrrolidine scaffold through a molecular hybridization approach and investigated their antileishmanial activity.

Parasitic diseases caused by trypanosomatid protozoa have long been treated with traditional methods. However, the effectiveness of current treatments for leishmaniasis is limited. Some are toxic, or have been abandoned, such as in the cases of Chagas disease and human African trypanosomiasis (HAT), commonly known as sleeping sickness.